



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

001 12/4/96

Reagent: ☼ rVV NS5A

Catalog Number: 9429

Lot Number:

Provided: 50 µl vial cell-free virus. 1.3×10^9 pfu/ml. Crude virus preparation generated from infection of BSC40 cells.

Host or Recommended Host or Host Cells: BSC40, 143B. Media requirements are DMEM, 90%; FBS, 10% for uninfected host cells. DMEM, 90%; FBS, 10% and 25 µg/ml 5'-bromodeoxyuridine for infected host cells.

Cloning Vector: Sc11

Description: The vaccinia was modified by the insertion of HCV gene(s) into *Bgl* II site of the vector. Genes expressed are HCV-1 (NS5A, truncated) (aa 2005-2396). Vaccinia late 11K, early-late 7.5K promoter sequences are present.

Special Characteristics: Virus can be used for gene expression studies and cellular immunity studies. Sterility: Negative for mycoplasma, bacteria and fungi.

Recommended Storage: -70degreeC.

Contributor: Chiron Corporation.

References: Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL, Houghton M, Walker BD. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. *J Clin Invest* **96**:2311-2321, 1995.
Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P, Walker CM. Analysis of a successful immune response against hepatitis C virus. *Immunity* **10**:439-449, 1999.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: rVV NS5A from Chiron Corporation." Material provided should be propagated to obtain sufficient quantities for intended use (Karschin A. et al. *Methods Enzymol* **207**:408-423, 1992).

Last Updated:

December 09, 2014

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.